Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion

Objective. The aim of the study is to investigate the clinical value of matrix metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) combined with adenosine deaminase (ADA) in pleural effusion and serum in benign and malignant pleural exudative effusion (PEE). Methods. A...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhiyang Xu, Jun Guan, Jianxin Xu, Jiahua Tu, Jiangdong Cheng
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Emergency Medicine International
Online Access:http://dx.doi.org/10.1155/2022/1615058
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850232575503630336
author Zhiyang Xu
Jun Guan
Jianxin Xu
Jiahua Tu
Jiangdong Cheng
author_facet Zhiyang Xu
Jun Guan
Jianxin Xu
Jiahua Tu
Jiangdong Cheng
author_sort Zhiyang Xu
collection DOAJ
description Objective. The aim of the study is to investigate the clinical value of matrix metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) combined with adenosine deaminase (ADA) in pleural effusion and serum in benign and malignant pleural exudative effusion (PEE). Methods. A total of 119 adult patients with PEE admitted in our hospital from May 2018 to October 2021 were selected. According to the patient’s condition, the patients were divided into the benign group (n = 75) and the malignant group (n = 44). The levels of MMP-3, CYFRA21-1, and ADA in pleural effusion and serum were detected. The receiver operating characteristic (ROC) curve was used to analyze the individual and combined predictive value of MMP-3, CYFRA21-1, and ADA levels. Results. In the malignant group, the pleural effusion and serum MMP-3 and CYFRA21-1 levels were higher than those in the benign group and the ADA levels were lower than those in the benign group (P < 0.05). In the malignant group, the positive detection rate of pleural effusion and serum MMP-3 and CYFRA21-1 was higher than that in the benign group and the positive detection rate of pleural effusion and serum ADA were lower than that in the benign group (P < 0.05). The AUC of pleural effusion MMP-3, serum MMP-3 and the combination of them in the diagnosis of PEE were 0.764, 0.722 and 0.810, respectively. The AUC of pleural effusion CYFRA21-1 and serum CYFRA21-1 and combination of them in the diagnosis of PEE were 0.776, 0.748 and 0.822, respectively. The AUC of pleural effusion ADA, serum ADA and their combination in differential diagnosis of PEE were 0.762, 0.737 and 0.836, respectively. The AUC of pleural effusion and serum of MMP-3 and CYFRA21-1 combined with ADA for differential diagnosis of PEE was 0.923. Conclusions. The diagnostic efficacy of MMP-3 combined with CYFRA21-1 and ADA in pleural effusion and serum for benign and malignant PEE are better than single index, which has certain clinical values for the selection of early intervention scheme for PEE patients.
format Article
id doaj-art-0aa8b10e00274e2d9251b3d1fc551264
institution OA Journals
issn 2090-2859
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Emergency Medicine International
spelling doaj-art-0aa8b10e00274e2d9251b3d1fc5512642025-08-20T02:03:08ZengWileyEmergency Medicine International2090-28592022-01-01202210.1155/2022/1615058Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative EffusionZhiyang Xu0Jun Guan1Jianxin Xu2Jiahua Tu3Jiangdong Cheng4Department of Thoracic SurgeryDepartment of Thoracic SurgeryDepartment of Thoracic SurgeryDepartment of Thoracic SurgeryDepartment of Thoracic SurgeryObjective. The aim of the study is to investigate the clinical value of matrix metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) combined with adenosine deaminase (ADA) in pleural effusion and serum in benign and malignant pleural exudative effusion (PEE). Methods. A total of 119 adult patients with PEE admitted in our hospital from May 2018 to October 2021 were selected. According to the patient’s condition, the patients were divided into the benign group (n = 75) and the malignant group (n = 44). The levels of MMP-3, CYFRA21-1, and ADA in pleural effusion and serum were detected. The receiver operating characteristic (ROC) curve was used to analyze the individual and combined predictive value of MMP-3, CYFRA21-1, and ADA levels. Results. In the malignant group, the pleural effusion and serum MMP-3 and CYFRA21-1 levels were higher than those in the benign group and the ADA levels were lower than those in the benign group (P < 0.05). In the malignant group, the positive detection rate of pleural effusion and serum MMP-3 and CYFRA21-1 was higher than that in the benign group and the positive detection rate of pleural effusion and serum ADA were lower than that in the benign group (P < 0.05). The AUC of pleural effusion MMP-3, serum MMP-3 and the combination of them in the diagnosis of PEE were 0.764, 0.722 and 0.810, respectively. The AUC of pleural effusion CYFRA21-1 and serum CYFRA21-1 and combination of them in the diagnosis of PEE were 0.776, 0.748 and 0.822, respectively. The AUC of pleural effusion ADA, serum ADA and their combination in differential diagnosis of PEE were 0.762, 0.737 and 0.836, respectively. The AUC of pleural effusion and serum of MMP-3 and CYFRA21-1 combined with ADA for differential diagnosis of PEE was 0.923. Conclusions. The diagnostic efficacy of MMP-3 combined with CYFRA21-1 and ADA in pleural effusion and serum for benign and malignant PEE are better than single index, which has certain clinical values for the selection of early intervention scheme for PEE patients.http://dx.doi.org/10.1155/2022/1615058
spellingShingle Zhiyang Xu
Jun Guan
Jianxin Xu
Jiahua Tu
Jiangdong Cheng
Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
Emergency Medicine International
title Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
title_full Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
title_fullStr Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
title_full_unstemmed Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
title_short Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion
title_sort clinical value of pleural effusion and serum mmp 3 and cyfra21 1 combined with ada in differential diagnosis of pleural exudative effusion
url http://dx.doi.org/10.1155/2022/1615058
work_keys_str_mv AT zhiyangxu clinicalvalueofpleuraleffusionandserummmp3andcyfra211combinedwithadaindifferentialdiagnosisofpleuralexudativeeffusion
AT junguan clinicalvalueofpleuraleffusionandserummmp3andcyfra211combinedwithadaindifferentialdiagnosisofpleuralexudativeeffusion
AT jianxinxu clinicalvalueofpleuraleffusionandserummmp3andcyfra211combinedwithadaindifferentialdiagnosisofpleuralexudativeeffusion
AT jiahuatu clinicalvalueofpleuraleffusionandserummmp3andcyfra211combinedwithadaindifferentialdiagnosisofpleuralexudativeeffusion
AT jiangdongcheng clinicalvalueofpleuraleffusionandserummmp3andcyfra211combinedwithadaindifferentialdiagnosisofpleuralexudativeeffusion